Justine C Rutter
Overview
Explore the profile of Justine C Rutter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hassan M, Li Y, Ma M, Teng M, Byun W, Puvar K, et al.
Eur J Med Chem
. 2024 Sep;
279:116904.
PMID: 39341093
Chemically induced proximity modalities such as targeted protein degradation (TPD) hold promise for expanding the number of proteins that can be manipulated pharmacologically. However, current TPD strategies are often limited...
2.
Li Y, Ma M, Hassan M, Hunkeler M, Teng M, Puvar K, et al.
Nat Chem Biol
. 2024 Jul;
20(12):1640-1649.
PMID: 39075252
Molecular glues are proximity-inducing small molecules that have emerged as an attractive therapeutic approach. However, developing molecular glues remains challenging, requiring innovative mechanistic strategies to stabilize neoprotein interfaces and expedite...
3.
Nussbaum D, Martz C, Waters A, Barrera A, Liu A, Rutter J, et al.
NPJ Precis Oncol
. 2024 May;
8(1):124.
PMID: 38822082
Acquired resistance remains a major challenge for therapies targeting oncogene activated pathways. KRAS is the most frequently mutated oncogene in human cancers, yet strategies targeting its downstream signaling kinases have...
4.
Kelly L, Rutter J, Lin K, Ling F, Duchmann M, Latour E, et al.
Nat Cancer
. 2024 May;
5(7):1082-1101.
PMID: 38816660
Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in nonmalignant tissues. This obstacle can be minimized by targeting cancer...
5.
Meslin P, Kelly L, Benbarche S, Lecourt S, Lin K, Rutter J, et al.
NAR Genom Bioinform
. 2024 May;
6(2):lqae059.
PMID: 38800827
Recent advancements in shRNA and Cas protein technologies have enabled functional screening methods targeting genes or non-coding regions using single or pooled shRNA and sgRNA. CRISPR-based systems have also been...
6.
Yoon H, Rutter J, Li Y, Ebert B
J Clin Invest
. 2024 Jan;
134(1).
PMID: 38165043
The concept of induced protein degradation by small molecules has emerged as a promising therapeutic strategy that is particularly effective in targeting proteins previously considered "undruggable." Thalidomide analogs, employed in...
7.
Hassan M, Li Y, Ma M, Teng M, Byun W, Puvar K, et al.
bioRxiv
. 2023 Oct;
PMID: 37873358
Small molecules that can induce protein degradation by inducing proximity between a desired target and an E3 ligase have the potential to greatly expand the number of proteins that can...
8.
Tsai J, Aguirre J, Li Y, Brown J, Focht V, Kater L, et al.
Mol Cell
. 2023 Jul;
83(15):2753-2767.e10.
PMID: 37478846
Nuclear hormone receptors (NRs) are ligand-binding transcription factors that are widely targeted therapeutically. Agonist binding triggers NR activation and subsequent degradation by unknown ligand-dependent ubiquitin ligase machinery. NR degradation is...
9.
Wieder N, Fried J, Kim C, Sidhom E, Brown M, Marshall J, et al.
Cell Metab
. 2023 Apr;
35(5):887-905.e11.
PMID: 37075753
Cellular exposure to free fatty acids (FFAs) is implicated in the pathogenesis of obesity-associated diseases. However, there are no scalable approaches to comprehensively assess the diverse FFAs circulating in human...
10.
Li Z, Ji B, Dixit P, Tchourine K, Lien E, Hosios A, et al.
Nat Metab
. 2022 Jun;
4(6):711-723.
PMID: 35739397
Production of oxidized biomass, which requires regeneration of the cofactor NAD, can be a proliferation bottleneck that is influenced by environmental conditions. However, a comprehensive quantitative understanding of metabolic processes...